BioLight Reports First Quarter 2015 Financial Results
TEL-AVIV, Israel, June 1, 2015 /PRNewswire/ --
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015.
Operational Highlights:
- Reported clinical study findings that identified positive statistical correlations between the TeaRx™ test's diagnostic parameters and widely used benchmark tests for dry eye syndrome.
- Reported that a blinded, multi-center clinical study of the CellDetect® non-invasive test for detecting bladder cancer in urine successfully achieved its primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease.
- Completed an investment in OphRx, a newly-formed ophthalmic company that has in-licensed a drug-delivery platform that has the potential to enable more efficient and safer delivery of eye drops.
- Announced first IOPtiMate™ System sales in new territories as well as, subsequent to the end of Q1, the first sale of the IOPtiMate™ system procedures.
- Subsequent to the end of Q1, signed a strategic partnership with Rock-One International Holdings Ltd., designed to help BioLight maximize its presence within China, the second largest healthcare market in the world after the U.S.
Financial Results:
All dollar amounts are expressed in New Israeli Shekels ("NIS"), with a convenience U.S. dollar translation of NIS amounts provided using the rate of NIS 3.981 to US$1.00, the representative rate of exchange as of March 31, 2015, and results are reported in accordance with International Financial Reporting Standards.
For the three months ended March 31, 2015, BioLight's revenues were NIS 157,000 (US$ 39,000). The net loss for the first quarter of 2015 was approximately NIS 6.6 million (US$ 1.7 million), or NIS 0.01 loss per share, as compared to a net loss of approximately NIS 7.8 million (US$ $2.0 million), or NIS 0.02 loss per share, for Q1-2014.
BioLight ended the first quarter in a strong financial position. As of March 31, 2015, the Company had approximately NIS 23.9 million (US$ 6.0 million) in cash and short-term deposits, which did not include the approximately NIS 26.3 million (US$ 6.6 million) in funds raised through an upsized private placement in May 2015 as part of a new strategic partnership.
"We made progress on multiple fronts in the first quarter toward advancing the clinical and commercial development of both our ophthalmic and cancer diagnostics portfolios," commented BioLight's Chief Executive Officer, Suzana Nahum Zilberberg. "As the execution of our growth strategy continues through the year, we look forward to updating our stakeholders as events unfold."
The Company's financial statements and management's discussion and analysis are available on the Company's website at http://www.bio-light.co.il and on the OTCQX website at http://www.otcmarkets.com/stock/BLGTY/filings.
About BioLight Life Sciences Ltd.
BioLight invests in, manages and commercializes biomedical innovations grouped around defined medical conditions - ophthalmology and cancer diagnostics. The ophthalmic technologies include IOPtiMate™, a laser-based non-invasive surgical treatment for glaucoma; TeaRx™, a point-of-care multi-parameter diagnostic test for dry-eye syndrome; Eye-D®, a controlled release drug-delivery insert platform and a new technology a drug-delivery platform for the improvement of ocular molecule transmission; and OphRx, a drug delivery technology platform for ocular uses. The cancer diagnostic technologies include proprietary tests that are designated for bladder, cervical, multiple myeloma and other cancers.
Leading key investors, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India's largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.
For more information please visit the Company's website at http://www.bio-light.co.il.
CONTACTS:
BioLight
Itai Bar-Natan, CFO
Email: [email protected]
Tel: +972-73-2753400
SOURCE BioLight Life Sciences Investments
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article